Abstract
AbstractOrganotin(IV) complexes can be used in chemotherapy due to its lipophilicity which can be affected by the availability of Sn coordination bond and bond stabilization between ligand and Sn(IV). In this study, three types of tri-organotin(IV) complexes which are, Ph3SnL, Me3SnL, and Bu3SnL derived from Schiff base ligand were synthesized by the reaction of methyl dopa with p-dimethyaminobenzaldehyde. All prepared complexes were charechterised using nuclear magnetic resonance (1H NMR, 13C NMR, and 119Sn NMR. The 1H NMR). The results confirm the coordination of the organotin(IV) moieties to the ligand. The cytotoxicity of tri-organotin(IV) complexes was evaluated against the A549 human lung cancer cell using MTT assay. Ph3SnL showed a high cytotoxic effect among othger complexes, Bu3SnL also showed a significant cytotoxic effect, while Me3SnL demonstrated a relatively lower effects. These findings highlight the potential of the tri-organotin(IV) complexes, particularly Ph3SnL and Bu3SnL, as promising candidates for further modification as anticancer agents. The results obtained from this study can be used to understand the structure–activity of organotin(IV) complexes and their applications as anti-cancer activity.
Publisher
Springer Science and Business Media LLC
Reference40 articles.
1. Seebacher NA, Stacy AE, Porter GM, Merlot AM (2019) Clinical development of targeted and immune based anti-cancer therapies. J Exp Clin Cancer Res 38(1):156
2. Al Talebi Z, Farhood AS, Hadi AG (2023) A comprehensive review of organotin complexes: synthesis and diverse applications. Cancer Cell 8:20
3. Kumar M, Abbas Z, Tuli HS, Rani A (2020) Organotin complexes with promising therapeutic potential. Curr Pharmacol Rep 6:167–181
4. Graisa AM, Zainulabdeen K, Salman I, Al-Ani A, Mohammed R, Hairunisa N, Mohammed S, Yousif E (2022) Toxicity and anti-tumour activity of organotin (IV) compounds. Baghdad J Biochem Appl Biol Sci 3(02):99–108
5. Hadi AG, Jawad K, Ahmed DS, Yousif E (2019) Synthesis and biological activities of organotin (IV) carboxylates: a review. Syst Rev Pharm 10(1):26–31